A late-stage study of the drug Nexavar in skin cancer patients has been halted, because the drug wasn't extending patients' overall survival rate, said California-based Onyx Pharmaceuticals Inc. and partner Bayer.
An independent data monitoring committee determined the drug wouldn't meet the study's treatment goal of improved overall survival in patients, the Associated Press reported.
The companies said they'll look more closely at the results of the skin cancer study to determine if its data has any impact on other ongoing studies of Nexavar.
Nexavar is currently approved to treat liver and advanced kidney cancer, the AP reported.